{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T08:17:12Z","timestamp":1782980232999,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100011913","name":"Kaohsiung Veterans General Hospital","doi-asserted-by":"publisher","award":["KSVGH 110-139"],"award-info":[{"award-number":["KSVGH 110-139"]}],"id":[{"id":"10.13039\/501100011913","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This study aimed to determine whether drug doses per kilogram of lean body mass (LBM) were associated with dose-limiting toxicity (DLT) events in head and neck cancer (HNC) patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective cohort study included 179 HNC patients who underwent induction chemotherapy\u00a0(IC) at a medical center from May 1, 2014, to May 31, 2021. HNC patients\u2019 characteristics, tumor factors, IC regimen and dose, laboratory data, and body composition factors, including lean body mass (LBM) and skeletal muscle index (SMI), derived from CT, MRI, or PET scan images and drug dose per kilogram LBM were recorded. Dose-limiting toxicity (DLT) events were regarded as the primary outcome. Multivariate logistic regression was used to establish a novel risk score for DLT events by the abovementioned variables. The above-mentioned risk score was validated in another cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The overall DLT events during the first cycle of IC for 179 HNC patients was 24%. After stratifying by gender, docetaxel per kilogram LBM\u2009&gt;\u20092.52\u00a0mg\/kg (adjusted odds ratio [aOR]: 3.18; 95% confidence interval [CI], 1.25\u20138.09), pre-treatment glutamic pyruvic transaminase (GPT)\u2009&gt;\u200940 U\/L (aOR, 2.61; 95% CI, 1.03\u20136.64), and history of chronic liver diseases (aOR, 3.98; 95% CI, 1.03\u201315.46) were significant variables in male HNC patients. The DLT events risk was categorized by summation of the above-mentioned risk factors for male HNC patients. Three risk groups were stratified by overall event of 17.6%, 25.8%, and 75%. The above-mentioned risk score had an acceptable discriminatory ability in another validation cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Among male HNC patients treated with IC, docetaxel per kilogram LBM more than 2.52\u00a0mg\/kg, pre-treatment GPT\u2009&gt;\u200940 U\/L, and history of chronic liver disease were significant risk factors for DLT events. Identifying high-risk patients could help physicians prevent severe\/fatal complications among HNC patients undergoing IC, especially for the male individuals.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-10152-y","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T12:05:59Z","timestamp":1666353959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Chemotherapy dose per kilogram lean body mass increased dose-limiting toxicity event in male head and neck cancer with taxane and platinum-based induction therapy"],"prefix":"10.1186","volume":"22","author":[{"given":"Chuan-Jen","family":"Hung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bor-Hwang","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keng-Ming","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Ying","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Hao","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6249-1798","authenticated-orcid":false,"given":"Ching-Chih","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"key":"10152_CR1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"10152_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"10152_CR3","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, Souli\u00e8res D, Tahara M, de Castro G Jr, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394:1915\u201328.","journal-title":"Lancet"},{"key":"10152_CR4","doi-asserted-by":"crossref","unstructured":"Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer.\u00a0N Engl J Med.\u00a02008;359:1116\u201327.","DOI":"10.1056\/NEJMoa0802656"},{"key":"10152_CR5","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","volume":"381","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med. 2019;381:1124\u201335.","journal-title":"N Engl J Med"},{"key":"10152_CR6","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1097\/CAD.0000000000000977","volume":"31","author":"S Mezi","year":"2020","unstructured":"Mezi S, Pomati G, Botticelli A, Roberto M, Cerbelli B, Cirillo A, et al. Induction chemotherapy in nonlaryngeal human papilloma virus-negative high-risk head and neck cancer: a real-world experience. Anticancer Drugs. 2020;31:1074\u201383.","journal-title":"Anticancer Drugs"},{"key":"10152_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1470-2045(13)70011-1","volume":"14","author":"R Haddad","year":"2013","unstructured":"Haddad R, O\u2019Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013;14:257\u201364.","journal-title":"Lancet Oncol"},{"key":"10152_CR8","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1200\/JCO.2013.54.6309","volume":"32","author":"EE Cohen","year":"2014","unstructured":"Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014;32:2735\u201343.","journal-title":"J Clin Oncol"},{"key":"10152_CR9","doi-asserted-by":"publisher","first-page":"e1609","DOI":"10.1002\/onco.13822","volume":"26","author":"CM Nielson","year":"2021","unstructured":"Nielson CM, Bylsma LC, Fryzek JP, Saad HA, Crawford J. Relative dose intensity of chemotherapy and survival in patients with advanced stage solid tumor cancer: a systematic review and meta-analysis. Oncologist. 2021;26:e1609\u201318.","journal-title":"Oncologist"},{"key":"10152_CR10","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s12885-021-08128-5","volume":"21","author":"M Bernadach","year":"2021","unstructured":"Bernadach M, Lapeyre M, Dillies AF, Miroir J, Casile M, Moreau J, et al. Predictive factors of toxicity of TPF induction chemotherapy for locally advanced head and neck cancers. BMC Cancer. 2021;21:360.","journal-title":"BMC Cancer"},{"key":"10152_CR11","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.21873\/anticanres.13440","volume":"39","author":"T Mikoshiba","year":"2019","unstructured":"Mikoshiba T, Ozawa H, Saito S, Ikari Y, Nakahara N, Ito F, et al. Usefulness of hematological inflammatory markers in predicting severe side-effects from induction chemotherapy in head and neck cancer patients. Anticancer Res. 2019;39:3059\u201365.","journal-title":"Anticancer Res"},{"key":"10152_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.oraloncology.2017.05.012","volume":"71","author":"AW Wendrich","year":"2017","unstructured":"Wendrich AW, Swartz JE, Bril SI, Wegner I, de Graeff A, Smid EJ, et al. Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer. Oral Oncol. 2017;71:26\u201333.","journal-title":"Oral Oncol"},{"key":"10152_CR13","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.1016\/j.cllc.2016.09.008","volume":"18","author":"B Sj\u00f8blom","year":"2017","unstructured":"Sj\u00f8blom B, Benth J, Gr\u00f8nberg BH, Baracos VE, Sawyer MB, Fl\u00f8tten \u00d8, et al. Drug dose per kilogram lean body mass predicts hematologic toxicity from carboplatin-doublet chemotherapy in advanced non-small-cell lung cancer. Clin Lung Cancer. 2017;18:e129\u201336.","journal-title":"Clin Lung Cancer"},{"key":"10152_CR14","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1158\/1078-0432.CCR-06-3067","volume":"13","author":"CM Prado","year":"2007","unstructured":"Prado CM, Baracos VE, McCargar LJ, Mourtzakis M, Mulder KE, Reiman T, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res. 2007;13:3264\u20138.","journal-title":"Clin Cancer Res"},{"key":"10152_CR15","doi-asserted-by":"publisher","first-page":"pky053","DOI":"10.1093\/jncics\/pky053","volume":"2","author":"T Aagaard","year":"2018","unstructured":"Aagaard T, Roen A, Reekie J, Daugaard G, Brown PN, Specht L, et al. Development and validation of a risk score for febrile neutropenia after chemotherapy in patients with cancer: the FENCE score. JNCI Cancer Spectr. 2018;2:pky053.","journal-title":"JNCI Cancer Spectr"},{"key":"10152_CR16","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","volume":"17","author":"SB Edge","year":"2010","unstructured":"Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471\u20134.","journal-title":"Ann Surg Oncol"},{"key":"10152_CR17","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3322\/caac.21389","volume":"67","author":"WM Lydiatt","year":"2017","unstructured":"Lydiatt WM, Patel SG, O\u2019Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, et al. Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:122\u201337.","journal-title":"CA Cancer J Clin"},{"key":"10152_CR18","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/coa.13481","volume":"45","author":"SC Lin","year":"2020","unstructured":"Lin SC, Lin YS, Kang BH, Yin CH, Chang KP, Chi CC, et al. Sarcopenia results in poor survival rates in oral cavity cancer patients. Clin Otolaryngol. 2020;45:327\u201333.","journal-title":"Clin Otolaryngol"},{"key":"10152_CR19","doi-asserted-by":"publisher","first-page":"11765","DOI":"10.1038\/s41598-020-68797-3","volume":"10","author":"A Faron","year":"2020","unstructured":"Faron A, Sprinkart AM, Kuetting DLR, Feisst A, Isaak A, Endler C, et al. Body composition analysis using CT and MRI: intra-individual intermodal comparison of muscle mass and myosteatosis. Sci Rep. 2020;10:11765.","journal-title":"Sci Rep"},{"key":"10152_CR20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.oraloncology.2016.09.006","volume":"62","author":"JE Swartz","year":"2016","unstructured":"Swartz JE, Pothen AJ, Wegner I, Smid EJ, Swart KM, de Bree R, et al. Feasibility of using head and neck CT imaging to assess skeletal muscle mass in head and neck cancer patients. Oral Oncol. 2016;62:28\u201333.","journal-title":"Oral Oncol"},{"key":"10152_CR21","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1093\/annonc\/mdx810","volume":"29","author":"VE Baracos","year":"2018","unstructured":"Baracos VE, Arribas L. Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy. Ann Oncol. 2018;29:ii1\u20139.","journal-title":"Ann Oncol"},{"key":"10152_CR22","first-page":"857","volume":"11","author":"AH Lavan","year":"2016","unstructured":"Lavan AH, Gallagher PF, O\u2019Mahony D. Methods to reduce prescribing errors in elderly patients with multimorbidity. Clin Interv Aging. 2016;11:857\u201366.","journal-title":"Clin Interv Aging"},{"key":"10152_CR23","unstructured":"Cisplatin. Lexicomp. Updated Sep 21 2021. Accesed 29\u00a0Sep\u00a02021."},{"key":"10152_CR24","unstructured":"Decetaxel. Lexicomp. Updated Sep 20 2021. Accessed 29\u00a0Sep\u00a02021."},{"key":"10152_CR25","first-page":"5655","volume":"33","author":"S Gou\u00e9rant","year":"2013","unstructured":"Gou\u00e9rant S, Leheurteur M, Chaker M, Modzelewski R, Rigal O, Veyret C, et al. A higher body mass index and fat mass are factors predictive of docetaxel dose intensity. Anticancer Res. 2013;33:5655\u201362.","journal-title":"Anticancer Res"},{"key":"10152_CR26","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1470-2045(05)70255-2","volume":"6","author":"M Di Maio","year":"2005","unstructured":"Di Maio M, Gridelli C, Gallo C, Shepherd F, Piantedosi FV, Cigolari S, et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol. 2005;6:669\u201377.","journal-title":"Lancet Oncol"},{"key":"10152_CR27","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1093\/annonc\/mdq248","volume":"21","author":"K Shitara","year":"2010","unstructured":"Shitara K, Matsuo K, Takahari D, Yokota T, Shibata T, Ura T, et al. Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel. Ann Oncol. 2010;21:2403\u20139.","journal-title":"Ann Oncol"},{"key":"10152_CR28","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1111\/cas.13556","volume":"109","author":"T Kosaka","year":"2018","unstructured":"Kosaka T, Shinojima T, Morita S, Oya M. Prognostic significance of grade 3\/4 neutropenia in Japanese prostate cancer patients treated with cabazitaxel. Cancer Sci. 2018;109:1570\u20135.","journal-title":"Cancer Sci"},{"key":"10152_CR29","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1200\/JCO.2016.72.1076","volume":"35","author":"M Eisenberger","year":"2017","unstructured":"Eisenberger M, Hardy-Bessard AC, Kim CS, G\u00e9czi L, Ford D, Mourey L, et al. Phase III study comparing a reduced dose of cabazitaxel (20 mg\/m(2)) and the currently approved dose (25 mg\/m(2)) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA. J Clin Oncol. 2017;35:3198\u2013206.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10152-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-10152-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10152-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T12:08:23Z","timestamp":1666354103000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10152-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10152"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-10152-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,21]]},"assertion":[{"value":"4 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of the Institutional Review Board of Kaohsiung Veterans General Hospital approved the study protocol (KSVGH22-CT1-03). Because we did not use human participants or personally identifiable records in our analysis, the Institutional Review Board of Kaohsiung Veterans General Hospital decided to waive the informed consent for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declared they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1084"}}